| scholarly article | Q13442814 |
| P50 | author | Kwang-Hyun Cho | Q67137583 |
| P2093 | author name string | Won Do Heo | |
| Sung-Young Shin | |||
| Jong Hoon Lee | |||
| Jae-Kyung Won | |||
| Hee Won Yang | |||
| P2860 | cites work | Metabolic control analysis: biological applications and insights | Q21194892 |
| Cell signaling by receptor tyrosine kinases | Q24598357 | ||
| The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation | Q24616946 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway | Q24799816 | ||
| Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma | Q27629132 | ||
| RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer | Q27657185 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation | Q27851610 | ||
| Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 | ||
| Factors underlying sensitivity of cancers to small-molecule kinase inhibitors | Q28252845 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Phosphatidylinositol-3-OH kinase as a direct target of Ras | Q29620177 | ||
| Targeting the cancer kinome through polypharmacology | Q33893019 | ||
| Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis | Q34101667 | ||
| A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer | Q34106382 | ||
| Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. | Q37196175 | ||
| Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition | Q37331610 | ||
| Environment-mediated drug resistance: a major contributor to minimal residual disease | Q37582773 | ||
| Systems-biology approaches for predicting genomic evolution | Q37909892 | ||
| Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer | Q38445646 | ||
| A hidden incoherent switch regulates RCAN1 in the calcineurin-NFAT signaling network. | Q39617812 | ||
| PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers | Q39859169 | ||
| Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| Activation of phosphoinositide 3-kinase gamma by Ras. | Q40717916 | ||
| Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. | Q41836780 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| High-order combination effects and biological robustness | Q42554339 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers | Q43136770 | ||
| A robustness-based approach to systems-oriented drug design. | Q51062307 | ||
| Robustness against mutations in genetic networks of yeast. | Q52169621 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 153-163 | |
| P577 | publication date | 2012-05-04 | |
| P1433 | published in | Journal of Molecular Cell Biology | Q2456339 |
| P1476 | title | The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor | |
| P478 | volume | 4 |
| Q36169826 | Attractor landscape analysis of colorectal tumorigenesis and its reversion |
| Q47120750 | Biocompatibility of vertically aligned multi-walled carbon nanotube scaffolds for human breast cancer cell line MDA-MB-231. |
| Q39313461 | Cell type specificity of signaling: view from membrane receptors distribution and their downstream transduction networks |
| Q33671530 | Context-independent essential regulatory interactions for apoptosis and hypertrophy in the cardiac signaling network |
| Q92134153 | Coupled feedback regulation of nuclear factor of activated T-cells (NFAT) modulates activation-induced cell death of T cells |
| Q42287113 | Differential Tissue-specific and Pathway-specific Anti-obesity Effects of Green Tea and Taeumjowitang, a Traditional Korean Medicine, in Mice |
| Q35612549 | Disentangling the Complexity of HGF Signaling by Combining Qualitative and Quantitative Modeling |
| Q50538898 | Dissecting Cell-Fate Determination Through Integrated Mathematical Modeling of the ERK/MAPK Signaling Pathway. |
| Q64953229 | Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells. |
| Q38995370 | Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway |
| Q90481923 | FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells |
| Q45715391 | Fluorescence resonance energy transfer based quantitative analysis of feedforward and feedback loops in epidermal growth factor receptor signaling and the sensitivity to molecular targeting drugs |
| Q38402255 | Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells |
| Q38705548 | Inferring Intracellular Signal Transduction Circuitry from Molecular Perturbation Experiments |
| Q35552019 | Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. |
| Q37665359 | Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer |
| Q55122179 | MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. |
| Q92501735 | Modeling therapy resistance via the EGFR signaling pathway |
| Q48276915 | Network-based identification of feedback modules that control RhoA activity and cell migration |
| Q58024450 | Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma |
| Q35781521 | Oncogenic mutations of thyroid hormone receptor β. |
| Q55086907 | Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. |
| Q27852623 | Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. |
| Q48236551 | Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma |
| Q57050008 | Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation |
| Q49378719 | Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF‑7 cells in vitro and in vivo and its mechanism of action |
| Q90468026 | Signal flow control of complex signaling networks |
| Q37301884 | Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging |
| Q55360028 | Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer. |
| Q48251105 | Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression. |
| Q64247758 | Tensor clustering with algebraic constraints gives interpretable groups of crosstalk mechanisms in breast cancer |
| Q54274892 | The PI3K/AKT/mTOR interactive pathway. |
| Q39101573 | The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2. |
| Q51085252 | The hidden switches underlying RORα-mediated circuits that critically regulate uncontrolled cell proliferation. |
| Q38128540 | The merged basins of signal transduction pathways in spatiotemporal cell biology |
| Q37208975 | Unveiling Hidden Dynamics of Hippo Signalling: A Systems Analysis. |
Search more.